Origin and design
Melanotan-II was developed at the University of Arizona in the 1980s as part of a program characterising synthetic melanocortin agonists with pigmentation activity — an early research direction motivated by potential photoprotection applications. It is a cyclic heptapeptide with a lactam bridge between residues 4 and 10, conferring conformational rigidity around the His-Phe-Arg-Trp pharmacophore common to α-MSH and its analogs.
The cyclic constraint stabilises the receptor-active conformation and dramatically increases potency relative to linear α-MSH fragments. The result is a molecule with broad activity across MC1R, MC3R, MC4R, and MC5R — the four melanocortin receptors that share the α-MSH-derived pharmacophore. (MC2R, the ACTH receptor, has a different ligand specificity and is not engaged by Melanotan-II.)
Receptor pharmacology and receptor selectivity
Melanotan-II binds all four α-MSH-family receptors with sub-nanomolar to nanomolar affinity. This broad receptor engagement is the defining feature of the compound: pigmentation via MC1R on melanocytes, CNS effects via MC3R and MC4R in the hypothalamus, and additional peripheral effects via MC5R.
The broad activity has been both a research tool and a limitation. As a probe of the melanocortin system as a whole, Melanotan-II is useful precisely because it activates the family broadly. For studies aimed at isolating specific receptor contributions, selective agonists (setmelanotide for MC4R selectivity, for example) or receptor-selective antagonists are typically needed alongside Melanotan-II to disentangle mechanisms.
Pigmentation research
The earliest preclinical work on Melanotan-II focused on MC1R engagement and melanogenesis — the induction of eumelanin production in melanocytes as a photoprotective response. Reported endpoints in animal-model work include measurable skin darkening in defined preclinical exposure regimens, and mechanistic characterisation of MC1R / cAMP-dependent tyrosinase upregulation.
The pigmentation activity of Melanotan-II is more pronounced than of Melanotan-I (a linear α-MSH analog) and substantially more than of PT-141, which was designed specifically to reduce MC1R engagement while retaining CNS activity. Melanotan-II remains the reference compound in the preclinical melanogenesis literature that uses melanocortin agonists as tool compounds.
CNS and sexual-response research
The CNS activity of Melanotan-II — mediated primarily via MC3R and MC4R — was recognised in preclinical characterisation shortly after the pigmentation activity. Rodent behavioural work established effects on sexual response, feeding behaviour, and stress-response endpoints, opening the research directions later developed in the PT-141 program.
The animal-model work characterising sexual-response endpoints under Melanotan-II is the foundational literature that motivated separating pigmentary from neural activity — which the C-terminal truncation to produce PT-141 addressed. Both compounds are still used side by side in comparative preclinical work.
Comparative context: Melanotan-II, PT-141, setmelanotide
In the melanocortin-agonist landscape, Melanotan-II sits at one end of the receptor-selectivity spectrum — the broadly-active reference compound. PT-141 (bremelanotide) sits in the middle: a Melanotan-II derivative with reduced MC1R engagement but retained MC3R/MC4R/MC5R activity. Setmelanotide sits at the selective end: engineered specifically for MC4R selectivity, focused on obesity research.
The three compounds together illustrate how systematic modification of a common pharmacophore backbone can produce a receptor-selectivity gradient across the same receptor family — a case study in medicinal-chemistry-driven receptor selectivity within a peptide family.
Analytical characterisation
Melanotan-II is characterised by reversed-phase HPLC for purity and mass spectrometry for identity. The theoretical monoisotopic mass is approximately 1024 Da. Because Melanotan-II is a cyclic peptide with a lactam bridge, characterisation methods should be tuned to resolve the cyclic species from any linear precursor or ring-opened impurities.
The lactam bridge is essential for receptor engagement — the linear precursor is far less potent — so characterisation of the cyclic fraction is a key quality attribute. A well-characterised lot should show a dominant single peak at the expected mass with clear resolution from the linear form.
Reconstitution and storage
Lyophilised Melanotan-II is soluble in aqueous buffer and reconstituted with bacteriostatic or sterile water. As with any cyclic peptide, gentle handling protects the ring integrity; vigorous agitation or extreme pH excursions should be avoided.
Store lyophilised material sealed and cold; aliquot reconstituted material into single-use portions. Working-concentration stability should be characterised in the specific buffer system used.
Worked examples
Reconstituting a 10 mg Melanotan-II vial
- 01Bring the sealed vial to room temperature.
- 02Wipe the stopper with an alcohol swab.
- 03Add 2 mL of bacteriostatic water for a nominal 5 mg/mL working concentration.
- 04Let the diluent run down the inside wall of the vial. Do not spray onto the solid.
- 05Swirl gently until dissolved.
- 06Label with lot, concentration, diluent, and reconstitution date.
Storage protocol
- 01Lyophilised material: sealed and desiccated at 2–8 °C short-term or −20 °C long-term.
- 02Reconstituted material: refrigerated at 2–8 °C, aliquotted into single-use portions.
- 03Track freeze-thaw cycles per aliquot.
Frequently asked questions
How does Melanotan-II differ from PT-141?
PT-141 is Melanotan-II with the C-terminal amide residue removed. That truncation substantially reduces MC1R engagement — and the pigmentary activity associated with it — while retaining MC3R/MC4R/MC5R engagement. The two compounds are commonly compared side by side in preclinical melanocortin research.
Which melanocortin receptors does Melanotan-II engage?
MC1R, MC3R, MC4R, and MC5R — the four receptors that share the α-MSH-derived pharmacophore. Engagement is broad and sub-nanomolar to nanomolar in affinity. MC2R (the ACTH receptor) is not engaged.
Why is the lactam bridge important?
The bridge between residues 4 and 10 confers conformational rigidity around the His-Phe-Arg-Trp pharmacophore, stabilising the receptor-active form. The linear precursor is far less potent, so the state of the lactam is a key quality attribute in lot characterisation.
What analytical tests confirm identity and purity?
Reversed-phase HPLC quantifies purity, mass spectrometry confirms identity against the expected molecular weight near 1024 Da, and characterisation should resolve any linear (ring-opened) form.
How should reconstituted Melanotan-II be stored?
Refrigerated at 2–8 °C, aliquotted into single-use portions to minimise freeze-thaw exposure.
References
Selected published research referenced in this article.
- 01Al-Obeidi F, Hadley ME, Pettitt BM, Hruby VJ. Design of a new class of superpotent cyclic α-melanotropins based on quenched dynamic simulations. J Am Chem Soc. 1989;111(9):3413–3416.
- 02Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921–930. PubMed
- 03Wessells H, Fuciarelli K, Hansen J, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol. 1998;160(2):389–393. PubMed
- 04Dorr RT, Lines R, Levine N, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777–1784. PubMed
- 05Cone RD. Studies on the physiological functions of the melanocortin system. Endocr Rev. 2006;27(7):736–749. PubMed
- 06Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96–102. PubMed